Product
OXERVATE
1 clinical trial
2 indications
Indication
Neurotrophic KeratopathyIndication
Corneal ulcerClinical trial
A Prospective, Multicenter Trial to Evaluate Efficacy and Safety of Cenegermin-bkbj (20 mcg/mL) Ophthalmic Solution on Corneal Thickness Via Anterior Segment Optical Coherence Tomography (AS-OCT) in Stage 3 Neurotrophic KeratitisStatus: Active (not recruiting), Estimated PCD: 2025-06-27